Transcriptional control of cardiac fibroblast plasticity

Journal of Molecular and Cellular Cardiology

Volumn 91, Issue , 2016, Pages 52-60

  Lighthouse, Janet K ^a   Small, Eric M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cardiac fibroblast; Fibrosis; Heart; Myocardial infarction; Myofibroblast; Transcription

Indexed keywords

CALCINEURIN; CCAAT ENHANCER BINDING PROTEIN; MYOCARDIN; PROTEIN TCF21; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERUM RESPONSE FACTOR; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; MKL1 PROTEIN, HUMAN; RHOA PROTEIN, HUMAN; SRF PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL C;

CELL ACTIVATION; CELL FUNCTION; CELL PLASTICITY; CELL REGENERATION; HEART FIBROBLAST; HEART MUSCLE CELL; HUMAN; MYOFIBROBLAST; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; CARDIAC MUSCLE; CELL DIFFERENTIATION; CYTOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM;

ANIMALS; CALCINEURIN; CELL DIFFERENTIATION; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; MYOCARDIUM; MYOFIBROBLASTS; NFATC TRANSCRIPTION FACTORS; RHOA GTP-BINDING PROTEIN; SERUM RESPONSE FACTOR; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRPC CATION CHANNELS;

EID: 84953294032     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.12.016     Document Type: Review

References (189)

1. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am. J. Physiol. Heart Circ. Physiol. 2007, 293(3):H1883-H1891.
2. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009, 105(12):1164-1176.
3. Pinto A.R., Ilinykh A., Ivey M.J., Kuwabara J.T., D'Antoni M., Debuque R.J., et al. Revisiting cardiac cellular composition. Circ. Res. 2015.
4. Evans S.M. The multifaceted roles of cardiac fibroblasts. J. Mol. Cell. Cardiol. 2015.
5. Kochanek K.D., Murphy S.L., Xu J. Deaths: final data for 2011. Natl. Vital Stat. Rep. 2015, 63(3):1-120.
6. Smith C.L., Baek S.T., Sung C.Y., Tallquist M.D. Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ. Res. 2011, 108(12):e15-e26.
7. Dettman R.W., Denetclaw W., Ordahl C.P., Bristow J. Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart. Dev. Biol. 1998, 193(2):169-181.
8. Perez-Pomares J.M., Carmona R., Gonzalez-Iriarte M., Atencia G., Wessels A., Munoz-Chapuli R. Origin of coronary endothelial cells from epicardial mesothelium in avian embryos. Int. J. Dev. Biol. 2002, 46(8):1005-1013.
9. Mikawa T., Gourdie R.G. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev. Biol. 1996, 174(2):221-232.
10. Fang M., Xiang F.L., Braitsch C.M., Yutzey K.E. Epicardium-derived fibroblasts in heart development and disease. J. Mol. Cell. Cardiol. 2015.
11. Snider P., Standley K.N., Wang J., Azhar M., Doetschman T., Conway S.J. Origin of cardiac fibroblasts and the role of periostin. Circ. Res. 2009, 105(10):934-947.
12. Burstein B., Libby E., Calderone A., Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 2008, 117(13):1630-1641.
13. Liu A.C., Joag V.R., Gotlieb A.I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 2007, 171(5):1407-1418.
14. Hinton R.B., Yutzey K.E. Heart valve structure and function in development and disease. Annu. Rev. Physiol. 2011, 73:29-46.
15. Zhou B., von Gise A., Ma Q., Hu Y.W., Pu W.T. Genetic fate mapping demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian heart. Dev. Biol. 2010, 338(2):251-261.
16. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13(8):952-961.
17. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(48):18284-18289.
18. von Gise A., Pu W.T. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ. Res. 2012, 110(12):1628-1645.
19. Moore-Morris T., Guimaraes-Camboa N., Banerjee I., Zambon A.C., Kisseleva T., Velayoudon A., et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 2014, 124(7):2921-2934.
20. Ali S.R., Ranjbarvaziri S., Talkhabi M., Zhao P., Subat A., Hojjat A., et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 2014, 115(7):625-635.
21. Ubil E., Duan J., Pillai I.C., Rosa-Garrido M., Wu Y., Bargiacchi F., et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 2014, 514(7524):585-590.
22. Kong P., Christia P., Saxena A., Su Y., Frangogiannis N.G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 2013, 305(9):H1363-H1372.
23. Sempowski G.D., Borrello M.A., Blieden T.M., Barth R.K., Phipps R.P. Fibroblast heterogeneity in the healing wound. Wound Repair Regen. 1995, 3(2):120-131.
24. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 2010, 225(3):631-637.
25. Moore-Morris T., Guimaraes-Camboa N., Yutzey K.E., Puceat M., Evans S.M. Cardiac fibroblasts: from development to heart failure. J. Mol. Med. (Berl.) 2015, 93(8):823-830.
26. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Investig. Dermatol. 2007, 127(3):526-537.
27. Turner N.A., Porter K.E. Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair 2013, 6(1):5.
28. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 2010, 7(1):30-37.
29. Teekakirikul P., Eminaga S., Toka O., Alcalai R., Wang L., Wakimoto H., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J. Clin. Invest. 2010, 120(10):3520-3529.
30. Serini G., Bochaton-Piallat M.L., Ropraz P., Geinoz A., Borsi L., Zardi L., et al. The fibronectin domain ED-a is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J. Cell Biol. 1998, 142(3):873-881.
31. Mayer D.C., Leinwand L.A. Sarcomeric gene expression and contractility in myofibroblasts. J. Cell Biol. 1997, 139(6):1477-1484.
32. Hinz B., Gabbiani G. Cell-matrix and cell-cell contacts of myofibroblasts: role in connective tissue remodeling. Thromb. Haemost. 2003, 90(6):993-1002.
33. Manso A.M., Kang S.M., Plotnikov S.V., Thievessen I., Oh J., Beggs H.E., et al. Cardiac fibroblasts require focal adhesion kinase for normal proliferation and migration. Am. J. Physiol. Heart Circ. Physiol. 2009, 296(3):H627-H638.
34. Oka T., Xu J., Kaiser R.A., Melendez J., Hambleton M., Sargent M.A., et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ. Res. 2007, 101(3):313-321.
35. Ignotz R.A., Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 1986, 261(9):4337-4345.
36. Weber K.T., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10(1):15-26.
37. Benjamin I.J., Jalil J.E., Tan L.B., Cho K., Weber K.T., Clark W.A. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ. Res. 1989, 65(3):657-670.
38. Katoonizadeh A., Nevens F., Verslype C., Pirenne J., Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int. 2006, 26(10):1225-1233.
39. Sun M., Kisseleva T. Reversibility of liver fibrosis. Clin. Res. Hepatol. Gastroenterol. 2015.
40. Hogan B.L., Barkauskas C.E., Chapman H.A., Epstein J.A., Jain R., Hsia C.C., et al. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 2014, 15(2):123-138.
41. Poss K.D., Wilson L.G., Keating M.T. Heart regeneration in zebrafish. Science 2002, 298(5601):2188-2190.
42. Bergmann O., Bhardwaj R.D., Bernard S., Zdunek S., Barnabe-Heider F., Walsh S., et al. Evidence for cardiomyocyte renewal in humans. Science 2009, 324(5923):98-102.
43. Doering C.W., Jalil J.E., Janicki J.S., Pick R., Aghili S., Abrahams C., et al. Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc. Res. 1988, 22(10):686-695.
44. Elsharkawy A.M., Oakley F., Mann D.A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005, 10(5):927-939.
45. Lee Y.A., Wallace M.C., Friedman S.L. Pathobiology of liver fibrosis: a translational success story. Gut 2015, 64(5):830-841.
46. Camelo A., Dunmore R., Sleeman M.A., Clarke D.L. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Front. Pharmacol. 2014, 4:173.
47. Goffin J.M., Pittet P., Csucs G., Lussi J.W., Meister J.J., Hinz B. Focal adhesion size controls tension-dependent recruitment of alpha-smooth muscle actin to stress fibers. J. Cell Biol. 2006, 172(2):259-268.
48. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3(5):349-363.
49. van Putten S., Shafieyan Y., Hinz B. Mechanical control of cardiac myofibroblasts. J. Mol. Cell. Cardiol. 2015.
50. Furtado M.B., Costa M.W., Pranoto E.A., Salimova E., Pinto A.R., Lam N.T., et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ. Res. 2014, 114(9):1422-1434.
51. Hidai H., Bardales R., Goodwin R., Quertermous T., Quertermous E.E. Cloning of capsulin, a basic helix-loop-helix factor expressed in progenitor cells of the pericardium and the coronary arteries. Mech. Dev. 1998, 73(1):33-43.
52. Huang G.N., Thatcher J.E., McAnally J., Kong Y., Qi X., Tan W., et al. C/EBP transcription factors mediate epicardial activation during heart development and injury. Science 2012, 338(6114):1599-1603.
53. Lu J., Richardson J.A., Olson E.N. Capsulin: a novel bHLH transcription factor expressed in epicardial progenitors and mesenchyme of visceral organs. Mech. Dev. 1998, 73(1):23-32.
54. Moss J.B., Xavier-Neto J., Shapiro M.D., Nayeem S.M., McCaffery P., Drager U.C., et al. Dynamic patterns of retinoic acid synthesis and response in the developing mammalian heart. Dev. Biol. 1998, 199(1):55-71.
55. Moore A.W., McInnes L., Kreidberg J., Hastie N.D., Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 1999, 126(9):1845-1857.
56. Barnes R.M., Firulli B.A., VanDusen N.J., Morikawa Y., Conway S.J., Cserjesi P., et al. Hand2 loss-of-function in Hand1-expressing cells reveals distinct roles in epicardial and coronary vessel development. Circ. Res. 2011, 108(8):940-949.
57. Trembley M.A., Velasquez L.S., de Mesy Bentley K.L., Small E.M. Myocardin-related transcription factors control the motility of epicardium-derived cells and the maturation of coronary vessels. Development 2015, 142(1):21-30.
58. Braitsch C.M., Combs M.D., Quaggin S.E., Yutzey K.E. Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart. Dev. Biol. 2012, 368(2):345-357.
59. Acharya A., Baek S.T., Huang G., Eskiocak B., Goetsch S., Sung C.Y., et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 2012, 139(12):2139-2149.
60. Sazonova O., Zhao Y., Nurnberg S., Miller C., Pjanic M., Castano V.G., et al. Characterization of TCF21 downstream target regions identifies a transcriptional network linking multiple independent coronary artery disease loci. PLoS Genet. 2015, 11(5).
61. Ponticos M., Harvey C., Ikeda T., Abraham D., Bou-Gharios G. JunB mediates enhancer/promoter activity of COL1A2 following TGF-beta induction. Nucleic Acids Res. 2009, 37(16):5378-5389.
62. Ponticos M., Papaioannou I., Xu S., Holmes A.M., Khan K., Denton C.P., et al. Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum. 2015, 67(1):243-253.
63. Bujak M., Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74(2):184-195.
64. Schultz-Cherry S., Lawler J., Murphy-Ullrich J.E. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J. Biol. Chem. 1994, 269(43):26783-26788.
65. Sarrazy V., Koehler A., Chow M.L., Zimina E., Li C.X., Kato H., et al. Integrins alphavbeta5 and alphavbeta3 promote latent TGF-beta1 activation by human cardiac fibroblast contraction. Cardiovasc. Res. 2014, 102(3):407-417.
66. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 2003, 116(Pt 2):217-224.
67. Bujak M., Ren G., Kweon H.J., Dobaczewski M., Reddy A., Taffet G., et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007, 116(19):2127-2138.
68. Frangogiannis N.G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 2014, 11(5):255-265.
69. Derynck R. SMAD proteins and mammalian anatomy. Nature 1998, 393(6687):737-739.
70. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19(23):2783-2810.
71. Zawel L., Dai J.L., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998, 1(4):611-617.
72. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993, 122(1):103-111.
73. Qiu P., Ritchie R.P., Fu Z., Cao D., Cumming J., Miano J.M., et al. Myocardin enhances Smad3-mediated transforming growth factor-beta1 signaling in a CArG box-independent manner: smad-binding element is an important cis element for SM22alpha transcription in vivo. Circ. Res. 2005, 97(10):983-991.
74. Tomasek J.J., McRae J., Owens G.K., Haaksma C.J. Regulation of alpha-smooth muscle actin expression in granulation tissue myofibroblasts is dependent on the intronic CArG element and the transforming growth factor-beta1 control element. Am. J. Pathol. 2005, 166(5):1343-1351.
75. Gan Q., Yoshida T., Li J., Owens G.K. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ. Res. 2007, 101(9):883-892.
76. Imamura T., Takase M., Nishihara A., Oeda E., Hanai J., Kawabata M., et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997, 389(6651):622-626.
77. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997, 389(6651):631-635.
78. Dobaczewski M., Bujak M., Li N., Gonzalez-Quesada C., Mendoza L.H., Wang X.F., et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res. 2010, 107(3):418-428.
79. Biernacka A., Cavalera M., Wang J., Russo I., Shinde A., Kong P., et al. Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circ. Heart Fail. 2015, 8(4):788-798.
80. Zhao J., Shi W., Wang Y.L., Chen H., Bringas P., Datto M.B., et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 282(3):L585-L593.
81. Wang B., Hao J., Jones S.C., Yee M.S., Roth J.C., Dixon I.M. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am. J. Physiol. Heart Circ. Physiol. 2002, 282(5):H1685-H1696.
82. Yu H., Huang J., Wang S., Zhao G., Jiao X., Zhu L. Overexpression of Smad7 suppressed ROS/MMP9-dependent collagen synthesis through regulation of heme oxygenase-1. Mol. Biol. Rep. 2013, 40(9):5307-5314.
83. Wei L.H., Huang X.R., Zhang Y., Li Y.Q., Chen H.Y., Yan B.P., et al. Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling. Cardiovasc. Res. 2013, 99(4):665-673.
84. Shindo T., Manabe I., Fukushima Y., Tobe K., Aizawa K., Miyamoto S., et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 2002, 8(8):856-863.
85. Takeda N., Manabe I., Uchino Y., Eguchi K., Matsumoto S., Nishimura S., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 2010, 120(1):254-265.
86. Wang B., Haldar S.M., Lu Y., Ibrahim O.A., Fisch S., Gray S., et al. The kruppel-like factor KLF15 inhibits connective tissue growth factor (CTGF) expression in cardiac fibroblasts. J. Mol. Cell. Cardiol. 2008, 45(2):193-197.
87. Leenders J.J., Wijnen W.J., Hiller M., van der Made I., Lentink V., van Leeuwen R.E., et al. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J. Biol. Chem. 2010, 285(35):27449-27456.
88. Bagchi R.A., Czubryt M.P. Synergistic roles of scleraxis and Smads in the regulation of collagen 1alpha2 gene expression. Biochim. Biophys. Acta 2012, 1823(10):1936-1944.
89. Choi M.E., Ding Y., Kim S.I. TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. Semin. Nephrol. 2012, 32(3):244-252.
90. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 2002, 115(Pt 15):3193-3206.
91. Kompa A.R., See F., Lewis D.A., Adrahtas A., Cantwell D.M., Wang B.H., et al. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J. Pharmacol. Exp. Ther. 2008, 325(3):741-750.
92. Matsuoka H., Arai T., Mori M., Goya S., Kida H., Morishita H., et al. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 283(1):L103-L112.
93. See F., Thomas W., Way K., Tzanidis A., Kompa A., Lewis D., et al. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J. Am. Coll. Cardiol. 2004, 44(8):1679-1689.
94. Leivonen S.K., Lazaridis K., Decock J., Chantry A., Edwards D.R., Kahari V.M. TGF-beta-elicited induction of tissue inhibitor of metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between Smad3, p38alpha, and ERK1/2. PLoS One 2013, 8(2).
95. Stratton R., Rajkumar V., Ponticos M., Nichols B., Shiwen X., Black C.M., et al. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J. 2002, 16(14):1949-1951.
96. Chichger H., Vang A., O'Connell K.A., Zhang P., Mende U., Harrington E.O., et al. PKC delta and betaII regulate angiotensin II-mediated fibrosis through p38: a mechanism of RV fibrosis in pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2015, 308(8):L827-L836.
97. Rustad K.C., Wong V.W., Gurtner G.C. The role of focal adhesion complexes in fibroblast mechanotransduction during scar formation. Differentiation 2013, 86(3):87-91.
98. Wong V.W., Rustad K.C., Akaishi S., Sorkin M., Glotzbach J.P., Januszyk M., et al. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat. Med. 2012, 18(1):148-152.
99. Norman C., Runswick M., Pollock R., Treisman R. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell 1988, 55(6):989-1003.
100. Minty A., Kedes L. Upstream regions of the human cardiac actin gene that modulate its transcription in muscle cells: presence of an evolutionarily conserved repeated motif. Mol. Cell. Biol. 1986, 6(6):2125-2136.
101. Sun Q., Chen G., Streb J.W., Long X., Yang Y., Stoeckert C.J., et al. Defining the mammalian CArGome. Genome Res. 2006, 16(2):197-207.
102. Benson C.C., Zhou Q., Long X., Miano J.M. Identifying functional single nucleotide polymorphisms in the human CArGome. Physiol. Genomics 2011, 43(18):1038-1048.
103. Esnault C., Stewart A., Gualdrini F., East P., Horswell S., Matthews N., et al. Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. Genes Dev. 2014, 28(9):943-958.
104. Miano J.M. Serum response factor: toggling between disparate programs of gene expression. J. Mol. Cell. Cardiol. 2003, 35(6):577-593.
105. Olson E.N., Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat. Rev. Mol. Cell Biol. 2010, 11(5):353-365.
106. Du K.L., Ip H.S., Li J., Chen M., Dandre F., Yu W., et al. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol. Cell. Biol. 2003, 23(7):2425-2437.
107. Huang J., Cheng L., Li J., Chen M., Zhou D., Lu M.M., et al. Myocardin regulates expression of contractile genes in smooth muscle cells and is required for closure of the ductus arteriosus in mice. J. Clin. Invest. 2008, 118(2):515-525.
108. Li S., Wang D.Z., Wang Z., Richardson J.A., Olson E.N. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(16):9366-9370.
109. Small E.M., Warkman A.S., Wang D.Z., Sutherland L.B., Olson E.N., Krieg P.A. Myocardin is sufficient and necessary for cardiac gene expression in Xenopus. Development 2005, 132(5):987-997.
110. Wang D., Chang P.S., Wang Z., Sutherland L., Richardson J.A., Small E., et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 2001, 105(7):851-862.
111. Pipes G.C., Creemers E.E., Olson E.N. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006, 20(12):1545-1556.
112. Wang D.Z., Li S., Hockemeyer D., Sutherland L., Wang Z., Schratt G., et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(23):14855-14860.
113. Guettler S., Vartiainen M.K., Miralles F., Larijani B., Treisman R. RPEL motifs link the serum response factor cofactor MAL but not myocardin to Rho signaling via actin binding. Mol. Cell. Biol. 2008, 28(2):732-742.
114. Miralles F., Posern G., Zaromytidou A.I., Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003, 113(3):329-342.
115. Mouilleron S., Langer C.A., Guettler S., McDonald N.Q., Treisman R. Structure of a pentavalent G-actin*MRTF-A complex reveals how G-actin controls nucleocytoplasmic shuttling of a transcriptional coactivator. Sci. Signal. 2011, 4(177).
116. Cen B., Selvaraj A., Burgess R.C., Hitzler J.K., Ma Z., Morris S.W., et al. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol. Cell. Biol. 2003, 23(18):6597-6608.
117. Hinson J.S., Medlin M.D., Lockman K., Taylor J.M., Mack C.P. Smooth muscle cell-specific transcription is regulated by nuclear localization of the myocardin-related transcription factors. Am. J. Physiol. Heart Circ. Physiol. 2007, 292(2):H1170-H1180.
118. Selvaraj A., Prywes R. Expression profiling of serum inducible genes identifies a subset of SRF target genes that are MKL dependent. BMC Mol. Biol. 2004, 5:13.
119. Kuwahara K., Barrientos T., Pipes G.C., Li S., Olson E.N. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Mol. Cell. Biol. 2005, 25(8):3173-3181.
120. Sandbo N., Kregel S., Taurin S., Bhorade S., Dulin N.O. Critical role of serum response factor in pulmonary myofibroblast differentiation induced by TGF-beta. Am. J. Respir. Cell Mol. Biol. 2009, 41(3):332-338.
121. Posern G., Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol. 2006, 16(11):588-596.
122. Small E.M. The actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation. J. Cardiovasc. Transl. Res. 2012, 5(6):794-804.
123. Busche S., Descot A., Julien S., Genth H., Posern G. Epithelial cell-cell contacts regulate SRF-mediated transcription via Rac-actin-MAL signalling. J. Cell Sci. 2008, 121(Pt 7):1025-1035.
124. Elberg G., Chen L., Elberg D., Chan M.D., Logan C.J., Turman M.A. MKL1 mediates TGF-beta1-induced alpha-smooth muscle actin expression in human renal epithelial cells. Am. J. Physiol. Ren. Physiol. 2008, 294(5):F1116-F1128.
125. Leitner L., Shaposhnikov D., Mengel A., Descot A., Julien S., Hoffmann R., et al. MAL/MRTF-A controls migration of non-invasive cells by upregulation of cytoskeleton-associated proteins. J. Cell Sci. 2011, 124(Pt 24):4318-4331.
126. O'Connor J.W., Gomez E.W. Cell adhesion and shape regulate TGF-beta1-induced epithelial-myofibroblast transition via MRTF-A signaling. PLoS One 2013, 8(12).
127. Tomasek J.J., Vaughan M.B., Kropp B.P., Gabbiani G., Martin M.D., Haaksma C.J., et al. Contraction of myofibroblasts in granulation tissue is dependent on Rho/Rho kinase/myosin light chain phosphatase activity. Wound Repair Regen. 2006, 14(3):313-320.
128. Copaja M., Venegas D., Aranguiz P., Canales J., Vivar R., Catalan M., et al. Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts. Toxicol. Appl. Pharmacol. 2011, 255(1):57-64.
129. Zhou Y., Huang X., Hecker L., Kurundkar D., Kurundkar A., Liu H., et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Invest. 2013, 123(3):1096-1108.
130. Small E.M., Thatcher J.E., Sutherland L.B., Kinoshita H., Gerard R.D., Richardson J.A., et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ. Res. 2010, 107(2):294-304.
131. Kagiyama S., Matsumura K., Goto K., Otsubo T., Iida M. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. Regul. Pept. 2010, 160(1-3):133-139.
132. Velasquez L.S., Sutherland L.B., Liu Z., Grinnell F., Kamm K.E., Schneider J.W., et al. Activation of MRTF-A-dependent gene expression with a small molecule promotes myofibroblast differentiation and wound healing. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(42):16850-16855.
133. Crider B.J., Risinger G.M., Haaksma C.J., Howard E.W., Tomasek J.J. Myocardin-related transcription factors A and B are key regulators of TGF-beta1-induced fibroblast to myofibroblast differentiation. J. Investig. Dermatol. 2011, 131(12):2378-2385.
134. Luchsinger L.L., Patenaude C.A., Smith B.D., Layne M.D. Myocardin-related transcription factor-a complexes activate type I collagen expression in lung fibroblasts. J Biol Chem. 2011, 286(51):44116-44125.
135. Qiu P., Feng X.H., Li L. Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J. Mol. Cell. Cardiol. 2003, 35(12):1407-1420.
136. Morita T., Mayanagi T., Sobue K. Reorganization of the actin cytoskeleton via transcriptional regulation of cytoskeletal/focal adhesion genes by myocardin-related transcription factors (MRTFs/MAL/MKLs). Exp. Cell Res. 2007, 313(16):3432-3445.
137. Kam Y., Quaranta V. Cadherin-bound beta-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between beta-catenin pools. PLoS One 2009, 4(2).
138. El Sayegh T.Y., Arora P.D., Laschinger C.A., Lee W., Morrison C., Overall C.M., et al. Cortactin associates with N-cadherin adhesions and mediates intercellular adhesion strengthening in fibroblasts. J. Cell Sci. 2004, 117(Pt 21):5117-5131.
139. Ho A.T., Voura E.B., Soloway P.D., Watson K.L., Khokha R. MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function. J. Biol. Chem. 2001, 276(43):40215-40224.
140. Banerjee I., Yekkala K., Borg T.K., Baudino T.A. Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Ann. N. Y. Acad. Sci. 2006, 1080:76-84.
141. Masszi A., Fan L., Rosivall L., McCulloch C.A., Rotstein O.D., Mucsi I., et al. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. Am. J. Pathol. 2004, 165(6):1955-1967.
142. Masszi A., Di Ciano C., Sirokmany G., Arthur W.T., Rotstein O.D., Wang J., et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am. J. Physiol. Ren. Physiol. 2003, 284(5):F911-F924.
143. Fan L., Sebe A., Peterfi Z., Masszi A., Thirone A.C., Rotstein O.D., et al. Cell contact-dependent regulation of epithelial-myofibroblast transition via the rho-rho kinase-phospho-myosin pathway. Mol. Biol. Cell 2007, 18(3):1083-1097.
144. Speight P., Nakano H., Kelley T.J., Hinz B., Kapus A. Differential topical susceptibility to TGFbeta in intact and injured regions of the epithelium: key role in myofibroblast transition. Mol. Biol. Cell 2013, 24(21):3326-3336.
145. Charbonney E., Speight P., Masszi A., Nakano H., Kapus A. Beta-catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial-myofibroblast transition. Mol. Biol. Cell 2011, 22(23):4472-4485.
146. Baurand A., Zelarayan L., Betney R., Gehrke C., Dunger S., Noack C., et al. Beta-catenin downregulation is required for adaptive cardiac remodeling. Circ. Res. 2007, 100(9):1353-1362.
147. Duan J., Gherghe C., Liu D., Hamlett E., Srikantha L., Rodgers L., et al. Wnt1/betacatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 2012, 31(2):429-442.
148. Laeremans H., Rensen S.S., Ottenheijm H.C., Smits J.F., Blankesteijn W.M. Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovasc. Res. 2010, 87(3):514-523.
149. Muehlich S., Wang R., Lee S.M., Lewis T.C., Dai C., Prywes R. Serum-induced phosphorylation of the serum response factor coactivator MKL1 by the extracellular signal-regulated kinase 1/2 pathway inhibits its nuclear localization. Mol. Cell. Biol. 2008, 28(20):6302-6313.
150. Nakagawa K., Kuzumaki N. Transcriptional activity of megakaryoblastic leukemia 1 (MKL1) is repressed by SUMO modification. Genes Cells 2005, 10(8):835-850.
151. Hinson J.S., Medlin M.D., Taylor J.M., Mack C.P. Regulation of myocardin factor protein stability by the LIM-only protein FHL2. Am. J. Physiol. Heart Circ. Physiol. 2008, 295(3).
152. Philippar U., Schratt G., Dieterich C., Muller J.M., Galgoczy P., Engel F.B., et al. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol. Cell 2004, 16(6):867-880.
153. Alnajar A., Nordhoff C., Schied T., Chiquet-Ehrismann R., Loser K., Vogl T., et al. The LIM-only protein FHL2 attenuates lung inflammation during bleomycin-induced fibrosis. PLoS One 2013, 8(11).
154. Arsenian S., Weinhold B., Oelgeschlager M., Ruther U., Nordheim A. Serum response factor is essential for mesoderm formation during mouse embryogenesis. EMBO J. 1998, 17(21):6289-6299.
155. Li J., Zhu X., Chen M., Cheng L., Zhou D., Lu M.M., et al. Myocardin-related transcription factor B is required in cardiac neural crest for smooth muscle differentiation and cardiovascular development. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(25):8916-8921.
156. Li S., Chang S., Qi X., Richardson J.A., Olson E.N. Requirement of a myocardin-related transcription factor for development of mammary myoepithelial cells. Mol. Cell. Biol. 2006, 26(15):5797-5808.
157. Bernau K., Ngam C., Torr E.E., Acton B., Kach J., Dulin N.O., et al. Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis. Respir. Res. 2015, 16:45.
158. Evelyn C.R., Wade S.M., Wang Q., Wu M., Iniguez-Lluhi J.A., Merajver S.D., et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol. Cancer Ther. 2007, 6(8):2249-2260.
159. Hayashi K., Watanabe B., Nakagawa Y., Minami S., Morita T. RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling. PLoS One 2014, 9(2).
160. Haak A.J., Tsou P.S., Amin M.A., Ruth J.H., Campbell P., Fox D.A., et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J. Pharmacol. Exp. Ther. 2014, 349(3):480-486.
161. Johnson L.A., Rodansky E.S., Haak A.J., Larsen S.D., Neubig R.R., Higgins P.D. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm. Bowel Dis. 2014, 20(1):154-165.
162. Evelyn C.R., Bell J.L., Ryu J.G., Wade S.M., Kocab A., Harzdorf N.L., et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg. Med. Chem. Lett. 2010, 20(2):665-672.
163. Wilkins B.J., Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 2004, 322(4):1178-1191.
164. Herum K.M., Lunde I.G., Skrbic B., Florholmen G., Behmen D., Sjaastad I., et al. Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress. J. Mol. Cell. Cardiol. 2013, 54:73-81.
165. Gonzalez Bosc L.V., Layne J.J., Nelson M.T., Hill-Eubanks D.C. Nuclear factor of activated T cells and serum response factor cooperatively regulate the activity of an alpha-actin intronic enhancer. J. Biol. Chem. 2005, 280(28):26113-26120.
166. Davis J., Burr A.R., Davis G.F., Birnbaumer L., Molkentin J.D. A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev. Cell 2012, 23(4):705-715.
167. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93(2):215-228.
168. Berry J.M., Le V., Rotter D., Battiprolu P.K., Grinsfelder B., Tannous P., et al. Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ. Res. 2011, 109(4):407-417.
169. Yue Z., Xie J., Yu A.S., Stock J., Du J., Yue L. Role of TRP channels in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 2015, 308(3):H157-H182.
170. Huang H., Wang W., Liu P., Jiang Y., Zhao Y., Wei H., et al. TRPC1 expression and distribution in rat hearts. Eur. J. Histochem. 2009, 53(4).
171. Kuwahara K., Wang Y., McAnally J., Richardson J.A., Bassel-Duby R., Hill J.A., et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 2006, 116(12):3114-3126.
172. Nakayama H., Wilkin B.J., Bodi I., Molkentin J.D. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J. 2006, 20(10):1660-1670.
173. Makarewich C.A., Zhang H., Davis J., Correll R.N., Trappanese D.M., Hoffman N.E., et al. Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ. Res. 2014, 115(6):567-580.
174. Harada M., Luo X., Qi X.Y., Tadevosyan A., Maguy A., Ordog B., et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 2012, 126(17):2051-2064.
175. Saliba Y., Karam R., Smayra V., Aftimos G., Abramowitz J., Birnbaumer L., et al. Evidence of a role for fibroblast transient receptor potential canonical 3 Ca2+ channel in renal fibrosis. J. Am. Soc. Nephrol. 2015, 26(8):1855-1876.
176. Willems I.E., Havenith M.G., De Mey J.G., Daemen M.J. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am. J. Pathol. 1994, 145(4):868-875.
177. Driesen R.B., Nagaraju C.K., Abi-Char J., Coenen T., Lijnen P.J., Fagard R.H., et al. Reversible and irreversible differentiation of cardiac fibroblasts. Cardiovasc. Res. 2014, 101(3):411-422.
178. Vivar R., Humeres C., Ayala P., Olmedo I., Catalan M., Garcia L., et al. TGF-beta1 prevents simulated ischemia/reperfusion-induced cardiac fibroblast apoptosis by activation of both canonical and non-canonical signaling pathways. Biochim. Biophys. Acta 2013, 1832(6):754-762.
179. Hale T.M. Persistent phenotypic shift in cardiac fibroblasts: impact of transient renin angiotensin system inhibition. J. Mol. Cell. Cardiol. 2015.
180. D'Souza K.M., Biwer L.A., Madhavpeddi L., Ramaiah P., Shahid W., Hale T.M. Persistent change in cardiac fibroblast physiology after transient ACE inhibition. Am. J. Physiol. Heart Circ. Physiol. 2015, 309(8):H1346-H1353.
181. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142(3):375-386.
182. Song K., Nam Y.J., Luo X., Qi X., Tan W., Huang G.N., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485(7400):599-604.
183. Nam Y.J., Lubczyk C., Bhakta M., Zang T., Fernandez-Perez A., McAnally J., et al. Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. Development 2014, 141(22):4267-4278.
184. Zhao Y., Londono P., Cao Y., Sharpe E.J., Proenza C., O'Rourke R., et al. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nat. Commun. 2015, 6:8243.
185. Fu Y., Huang C., Xu X., Gu H., Ye Y., Jiang C., et al. Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails. Cell Res. 2015, 25(9):1013-1024.
186. Wang H., Cao N., Spencer C.I., Nie B., Ma T., Xu T., et al. Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4. Cell Rep. 2014, 6(5):951-960.
187. Mathison M., Singh V.P., Gersch R.P., Ramirez M.O., Cooney A., Kaminsky S.M., et al. "Triplet" polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors. J. Thorac. Cardiovasc. Surg. 2014, 148(4):1656-1664.
188. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485(7400):593-598.
189. Nagalingam R.S., Safi H.A., Czubryt M.P. Gaining myocytes or losing fibroblasts: challenges in cardiac fibroblast reprogramming for infarct repair. J. Mol. Cell. Cardiol. 2015.